×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CLDX – celldex therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CLDX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/20
08:05 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $46.00 price target on the stock.
Medium
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $46.00 price target on the stock.
3/4
08:01 am
cldx
Celldex Therapeutics to Present at Upcoming Investor Conferences
Medium
Report
Celldex Therapeutics to Present at Upcoming Investor Conferences
3/3
10:06 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $42.00 to $36.00. They now have a "neutral" rating on the stock.
Medium
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $42.00 to $36.00. They now have a "neutral" rating on the stock.
3/3
08:01 am
cldx
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
High
Report
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
3/1
07:07 pm
cldx
Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]
Medium
Report
Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]
3/1
12:45 pm
cldx
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
Medium
Report
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
2/28
08:13 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
2/27
07:19 pm
cldx
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/27/2025
04:01 pm
CLDX
celldex therapeutics, inc.
BEAT
Report
1.3%
celldex therapeutics, inc.
2/27/2025
04:01 pm
CLDX
celldex therapeutics, inc.
BEAT
Report
1.3%
celldex therapeutics, inc.
2/27/2025
04:01 pm
CLDX
celldex therapeutics, inc.
BEAT
Report
1.3%
celldex therapeutics, inc.
2/27/2025
04:01 pm
CLDX
celldex therapeutics, inc.
BEAT
Report
1.3%
celldex therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/27
04:06 pm
cldx
Form 10-K Celldex Therapeutics, For: Dec 31
Low
Report
Form 10-K Celldex Therapeutics, For: Dec 31
2/27
04:01 pm
cldx
Form 8-K Celldex Therapeutics, For: Feb 27
Low
Report
Form 8-K Celldex Therapeutics, For: Feb 27
2/14
05:16 pm
cldx
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Kynam Capital Management, LP
Low
Report
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Kynam Capital Management, LP
2/14
09:44 am
cldx
Form SCHEDULE 13G Celldex Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SCHEDULE 13G Celldex Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
2/12
09:28 am
cldx
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: FMR LLC
Medium
Report
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: FMR LLC
2/5
01:24 pm
cldx
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: BlackRock, Inc.
Low
Report
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/20
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
30.1%
4/28 Form DEF 14A Celldex Therapeutics, For: Jun 18 9.6%
3/26 Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus N/A ActVsEst N/A - N/A 3.4%
8/7 Q2/2019 6/30/2019 EPS -0.840 ZacksConsensus -1.170 ActVsEst 0.330 - Beat 2.3%
6/21 Form S-8 Celldex Therapeutics, 2.0%
10/2 Celldex Therapeutics Announces Upcoming Data Presentations 1.9%
10/9 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 1.4%
12/23 Is Celldex Therapeutics, Inc. (CLDX) A Good Stock To Buy? [Yahoo! Finance News] 1.3%
2/12 Form SC 13G Celldex Therapeutics, Filed by: RENAISSANCE TECHNOLOGIES LLC 0.4%
5/24 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 0.4%
4/28 Form DEF 14A Celldex Therapeutics, For: Jun 18 9.6%
3/26 Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus N/A ActVsEst N/A - N/A 3.4%
8/7 Q2/2019 6/30/2019 EPS -0.840 ZacksConsensus -1.170 ActVsEst 0.330 - Beat 2.3%
6/21 Form S-8 Celldex Therapeutics, 2.0%
10/2 Celldex Therapeutics Announces Upcoming Data Presentations 1.9%
10/9 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 1.4%
12/23 Is Celldex Therapeutics, Inc. (CLDX) A Good Stock To Buy? [Yahoo! Finance News] 1.3%
2/12 Form SC 13G Celldex Therapeutics, Filed by: RENAISSANCE TECHNOLOGIES LLC 0.4%
5/24 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 0.4%
TOP News Decliners
3/27
Form 424B5 Celldex Therapeutics,
-12.3%
6/1 Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma -9.6%
11/8 CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study -9.2%
12/6 Form S-3 Celldex Therapeutics, -9.1%
11/12 Q3/2019 9/30/2019 EPS -0.750 ZacksConsensus -0.840 ActVsEst 0.090 - Beat -7.3%
11/18 Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159 -5.9%
3/3 Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program -4.6%
5/7 Q1/2019 3/31/2019 EPS -1.400 ZacksConsensus -1.140 ActVsEst (0.260) - Miss -3.6%
5/8 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was given a new $19.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -2.8%
7/31 Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call -2.8%
6/1 Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma -9.6%
11/8 CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study -9.2%
12/6 Form S-3 Celldex Therapeutics, -9.1%
11/12 Q3/2019 9/30/2019 EPS -0.750 ZacksConsensus -0.840 ActVsEst 0.090 - Beat -7.3%
11/18 Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159 -5.9%
3/3 Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program -4.6%
5/7 Q1/2019 3/31/2019 EPS -1.400 ZacksConsensus -1.140 ActVsEst (0.260) - Miss -3.6%
5/8 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was given a new $19.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -2.8%
7/31 Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: